However, some patients relapse or present with de novo metastatic disease. For those not recently exposed to platinum-based therapies, the standard of care includes gemcitabine, cisplatin, and the ...

Adjuvant camrelizumab significantly improves event-free survival in patients with locoregionally advanced nasopharyngeal carcinoma, new data suggest.

Chinese scientists have developed a new treatment for nasopharyngeal carcinoma that helps patients live longer and have a better quality of life compared with traditional therapies that often ...